Applied Genetic Technologies Corp., backed by technology from the University of Florida, raises $37.5m in a record area venture round.

Applied Genetic Technologies Corp. (AGTC), a US-based biotechnology company that receives much of its technology licenced from the University of Florida, has raised a $37.5m series B round.

GlaxoSmithKline’s venture unit SR One led the round along with life science venture firm Alta Partners. They were joined by new investor Osage University Partners, a venture fund that invests in university start-ups. Also joining the round were existing venture firm investors Intersouth Partners, InterWest, and MedImmune Ventures.

Intersouth, InterWest, and MedImmune…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?